论文部分内容阅读
目的:评价胺碘酮用于危重症患者合并快速心律失常时的疗效和安全性。方法:对合并快速心律失常的78例危重症患者,静脉注射胺碘酮,记录心律失常转复为窦性心律,或心率减慢、期前收缩减少的百分率,密切监测用药前后血压、心率、药物不良反应及心力衰竭情况。结果:78例患者中,总有效率为80.76%,无效为19.24%,无明显的心力衰竭加重,无严重药物不良反应。结论:静脉注射胺碘酮对合并快速型心律失常的危重症患者是安全和有效的。
Objective: To evaluate the efficacy and safety of amiodarone in the treatment of critically ill patients with tachyarrhythmia. Methods: 78 critically ill patients with tachyarrhythmia were given intravenous amiodarone. The arrhythmia was recorded as sinus rhythm, or the heart rate was slowed down. The percentage of premature systole reduction was monitored. The blood pressure, heart rate, Adverse drug reactions and heart failure. Results: Of the 78 patients, the total effective rate was 80.76%, and the ineffective rate was 19.24%. There was no obvious worsening of heart failure and no serious adverse drug reactions. Conclusion: Intravenous amiodarone is safe and effective for critically ill patients with tachyarrhythmia.